Business
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
CAMBRIDGE, Mass., May 13, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) issued to Enveric US Patent No. 12,605,361 (the ’361 patent), titled, "Carboxylated Psilocybin Derivatives and Methods of Using," pertaining to the Company’s EVM301 Series of molecules being d
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c135a52ec620d45070afae3d2fd0b022"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f2ti0Jvik6z6uMHcSB7R9Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c135a52ec620d45070afae3d2fd0b022","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CNpwEtTaLbVbyEvdlsFS2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c135a52ec620d45070afae3d2fd0b022","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/g61ZmYXWPPPa3B13iut4BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c135a52ec620d45070afae3d2fd0b022","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Claims to methods for treating a psychiatric disorder using novel pharmaceutical drug formulations encompass an EVM301 Series of drug candidates of carboxylated psilocybin derivatives, targeting various difficult-to-treat mental health disorders","length":245,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 13, 2026--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the United States Patent and Trademark Office (USPTO) issued to Enveric US Patent No. 12,605,361 (the ’361 patent), titled, "Carboxylated Psilocybin Derivatives and Methods of Using," pertaining to the Company’s EVM301 Series of molecules being developed as potential treatments for mental health disorders.","length":608,"tagName":"p"},{"type":"text","content":"The ‘361 patent, which issued on April 21, 2026, is directed to method claims that cover the use of Enveric’s previously patented pharmaceutical drug formulations claimed in U.S. Patent No. 11,752,130. The additional patent coverage broadens patent protection by covering use of the novel molecular structures for a family of carboxylated derivatives of tryptamine-based drug candidates. This patent is another step forward in b...